Back to Trial

Oracle Runs

Oracle findings and outcome history for Efficacy of VTP-300 in Chronic Hepatitis B Infection (NCT05343481).

Runs
1
Findings
1
Latest Run
Apr 1, 2026, 6:51 PM
Resolution Evidence
Outcome
YES
Status
Resolved
Settlement Date
4/1/26 UTC
Executive Summary

Exact trial NCT05343481 had a trial-specific public interim readout framed positively: Barinthus reported HBsAg loss in 8 participants, 2 functional cures, and said the Phase 2 data were “incredibly encouraging.” Independent conference coverage also described the regimen as showing potential for HBV cure.

Sources
Sponsorinvestors.barinthusbio.com11/15/24
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

For HBV003/NCT05343481, Barinthus reported 8 participants with HBsAg loss, 2 meeting functional cure criteria, generally good tolerability, and called the Phase 2 data “incredibly encouraging.”

View source
Web Searchhcplive.com11/12/23
VTP-300 Plus Nivolumab Lowers HBsAG, Shows Potential for HBV Cure Regimen

Coverage of the ongoing HBV003 Phase 2b trial said interim data showed HBsAg reductions and highlighted a potential role for VTP-300 plus nivolumab in functionally curing HBV.

View source
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

YESAccepted90% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

Exact trial NCT05343481 had a trial-specific public interim readout framed positively: Barinthus reported HBsAg loss in 8 participants, 2 functional cures, and said the Phase 2 data were “incredibly encouraging.” Independent conference coverage also described the regimen as showing potential for HBV cure.

Found Apr 1, 2026, 6:51 PMOutcome date Nov 15, 2024, 12:00 AMReviewed Apr 1, 2026, 7:04 PM
Sponsorinvestors.barinthusbio.comNov 15, 2024, 12:00 AM
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
For HBV003/NCT05343481, Barinthus reported 8 participants with HBsAg loss, 2 meeting functional cure criteria, generally good tolerability, and called the Phase 2 data “incredibly encouraging.”
Web Searchhcplive.comNov 12, 2023, 12:00 AM
VTP-300 Plus Nivolumab Lowers HBsAG, Shows Potential for HBV Cure Regimen
Coverage of the ongoing HBV003 Phase 2b trial said interim data showed HBsAg reductions and highlighted a potential role for VTP-300 plus nivolumab in functionally curing HBV.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

Accepted Oracle Review (Legacy)Apr 1, 2026, 7:04 PM

Will the results be positive?

PendingtoYEScurrentYES
GPT-5.4 (OpenAI)90% confidenceReviewed Apr 1, 2026, 7:04 PM

Exact trial NCT05343481 had a trial-specific public interim readout framed positively: Barinthus reported HBsAg loss in 8 participants, 2 functional cures, and said the Phase 2 data were “incredibly encouraging.” Independent conference coverage also described the regimen as showing potential for HBV cure.